Retinal neovascularisation without ischaemia in the spontaneously diabetic Torii rat
- First Online:
- Cite this article as:
- Yamada, H., Yamada, E., Higuchi, A. et al. Diabetologia (2005) 48: 1663. doi:10.1007/s00125-005-1809-0
The spontaneously diabetic Torii (SDT) rat has recently been established as a model of type 2 human diabetes mellitus. Male SDT rats develop severe diabetic ocular complications. This study investigated the nature of the ocular complications in this model and addressed the question of whether the SDT rat is a good model of human proliferative diabetic retinopathy.
Male SDT rats aged 50 weeks were studied for a period of 8 months. Under deep anaesthesia, one eye of each animal was enucleated following perfusion with fluorescein dextran and a retinal flat mount was prepared to study vascular structure. The other eye was enucleated and investigated histologically by haematoxylin–eosin and azan staining and by immunohistochemistry using antibodies against vascular endothelium (Griffonia simplicifolia isolectin B4 antibody) and vascular endothelial growth factor (VEGF).
From the vascular structure study, 17 of 32 rats (53%) showed proliferative retinopathy without vascular non-perfusion. The histological study revealed traction retinal folds in rats with proliferative retinopathy. Azan staining showed some proliferative matrix in rats with normal retinal structure and those with proliferative retinopathy compared with normoglycaemic controls. Staining with Griffonia simplicifolia isolectin B4 antibody showed no specific vascular changes in any of the rats, while VEGF staining revealed higher immunoreactivity in the retina of rats with normal retinal structure and those with proliferative retinopathy, but only low immunoreactivity in the control animals.
There appear to be differences between the SDT rat model of diabetic retinopathy and human proliferative diabetic retinopathy, as the SDT rat develops retinal neovascularisation without retinal ischaemia. This very unique display of ocular neovascularisation may be caused by increased expression of VEGF.
KeywordsProliferative diabetic retinopathyRetinal neovascularisationSpontaneously diabetic Torii ratType 2 diabetesVascular endothelial growth factor
Griffonia simplicifolia isolectin B4 antibody
spontaneously diabetic Torii
control SDT rat with normoglycaemia
SDT rat with normal retinal structure
SDT rat with proliferative retinopathy
vascular endothelial growth factor
To provide valuable information on the pathogenesis of human diabetic retinopathy, several animal models of diabetic retinopathy have been established. Despite many attempts to establish suitable models that accurately reflect the human condition, there are very few animal models that develop severe diabetic retinopathy with large areas of retinal non-perfusion and retinal neovascularisation [1–3]. In dog models of diabetic retinopathy, it is necessary to wait at least 5 years before severe retinopathy accompanied by retinal neovascularisation is observed . Rodent models are generally preferred for the following reasons: (1) they have a similar genetic background to humans; (2) various experimental tools, including antibodies to certain peptides, are widely available; (3) they have short reproductive cycles; and (4) the animals are easy to handle. Several kinds of rodent model are now available for research into diabetes mellitus. These include the BioBreeding rat , the streptozotocin (STZ) rat or alloxan-induced diabetic rat  and the non-obese diabetic mouse  as models of type 1 diabetes, and the Zucker diabetic fatty rat , the BHE (Bureau of Home Economics) rat , the Otsuka–Long–Evans–Tokushima fatty rat  and the diet-induced diabetic rat or mouse as models of type 2 diabetes. Although the majority of these models develop significant diabetic retinal microvascular lesions, none have severe retinal changes such as pre-retinal neovascularisation or extensive areas of retinal reperfusion .
The spontaneously diabetic Torii (SDT) rat is an inbred rat strain established recently from a colony of normal Sprague–Dawley rats . Male SDT rats develop hyperglycaemia spontaneously without obesity at 20 weeks of age, with an incident rate reaching 100% at 40 weeks of age. As a result, the animals develop severe ocular complications such as cataracts, retinal neovascularisations and retinal detachment, which are similar to the diabetic ocular complications seen in humans .
To assess whether the SDT rat is a suitable animal model of human proliferative diabetic retinopathy we compared the nature of retinal neovascularisation in these rats with that of the human condition, focusing on the relationship between vascular endothelial growth factor (VEGF) and retinal vascular changes.
Materials and methods
The SDT rats used in this study were male and were aged 50 weeks, as only male animals were supplied from the animal control centre of the SDT rat study group (Torii Pharmaceutical Company, Tokyo, Japan) and we had to wait 50 weeks until all the animals had a blood glucose level of above 2.22 mmol/L. All the rats were confirmed as having diabetes mellitus by checking that their serum blood glucose was above 2.22 mmol/L. A total of 50 ‘diabetic’ SDT rats were housed in the animal facility at Kansai Medical University with a room temperature of 22°C, humidity levels of 20–30% and controlled lighting automatically set to a diurnal rhythm. The wood-chip carpet and drinking water in the cages were changed daily to improve hygiene conditions and prevent infection. Blood sugar concentration was checked monthly. After 8 months all the rats were killed. Under deep ether anaesthesia, one eye from each rat was enucleated, immediately frozen using liquid nitrogen, and embedded in optimal cutting temperature compound. The rats were then perfused with fluorescein dextran for a flat mount vascular structure study. During the 8-month observation period we came across an SDT rat strain from another colony group that remained normoglycaemic. These rats were used as age-matched controls for the flat mount and histological studies.
The study was performed in accordance with the ARVO (Association for Research in Vision and Ophthalmology) Resolution on the Use of Animals in Research.
Histology and immunohistochemistry
Frozen 10-µm sections were taken from the eyes of the SDT rats and stained with haematoxylin and eosin (HE) staining, Azan staining and immunohistochemically with antibodies including biotinylated Griffonia simplicifolia isolectin B4 (GSA; Vector Laboratories, Burlingame, CA, USA) and anti-VEGF (Santa Cruz Biotechnology, Santa Cruz, CA, USA). For immunohistochemistry staining, the slides were fixed in 4% paraformaldehyde-PBS (pH 7.4) for 10 min, and washed with 0.05 mol/l PBS. The slides were then incubated for 30 min in ice-cold methanol/H2O2, washed with PBS and incubated for 30 min in 10% normal swine serum. After excess serum was removed from the slides, they were incubated for 12 h at 4°C with each antibody. After rinsing with Tris-buffered saline, the slides were incubated for 30 min at room temperature with biotin-conjugated goat anti-mouse or anti-rat antibody (DakoCytomation, Glostrup, Denmark). For the anti-GSA staining, this incubation was omitted as the antibody was already biotin conjugated. The slides were then rinsed with PBS and incubated for 30 min at room temperature with avidin coupled to peroxidase (DakoCytomation). After washing with PBS for a further 10 min, the slides were colourised with Simple Stain AEC (Nichirei) to give a red reaction product, and mounted with Aqua Poly/Mount (Polysciences, Warrington, PA, USA).
Preparation of retinal flat mounts
The rats were deeply anaesthetised using ether, and the descending aorta was clamped and the right atrium cut. This was followed by infusion of 3 ml PBS containing 50 mg/ml fluorescein-labelled dextran (average molecular weight: 2×106; Sigma, St Louis, MO, USA) through the left ventricle. This procedure was similar to that described previously by Smith et al. in a mouse model . The eyes were then fixed for 1 h in 10% buffered formalin followed by separation and excision of the cornea, lens and retina with the aid of a microscope. The retinae were cut radially from the edge to the equator, with several incisions made in each eye, and then flat mounted in Aqua Poly/Mount with the vitreous side facing upwards. The flat mounts were examined using a fluorescent microscope (BH-2; Olympus, Tokyo, Japan), and the images were downloaded onto a computer and printed using a Pictrostat 3000 photoprinter (Fuji Photo Film, Tokyo, Japan).
Male SDT rats exhibit spontaneous glucose intolerance with impaired insulin secretion at 14 weeks of age, and by 20 weeks of age, they develop diabetes with marked hyperglycaemia and hypoinsulinaemia accompanied by decreased body weight and body mass index [11, 13]. The SDT rat is thought to be a non-obese animal model of human type 2 diabetes, as it develops tissue damage in pancreatic islets equivalent to the dysfunction of pancreatic islet tissue that plays a major role in the development of human diabetes. As the SDT rat can survive for a long time without insulin treatment, it is considered a useful model of type 2 human diabetes mellitus. The main difference between the SDT rat model and other rodent models of diabetes is that these rats develop severe ocular complications such as neovascularisation and tractional changes in the retina. There is no rodent model of severe diabetic retinopathy, and the SDT rat may be a very good candidate.
However, in contrast to humans with diabetic retinopathy, the SDT rat does not develop vascular non-perfusion, bleeding, hard exudates or soft exudates in the retina. In this study, only 53% of the rats were found to have proliferative retinal changes. These proliferative changes were caused by retinal neovascularisation originating in the optic disc. Azan staining showed that the tractional changes may have been due to alterations in vitreo-retinal interaction, very similar to the changes that occur in human proliferative diabetic retinopathy.
It is already very clear that VEGF plays a key role in the development of diabetic ocular complications in human eyes, such as ocular neovascularisation and blood ocular barrier breakdown [14–18]. Increased levels of VEGF have also been detected in the eyes of diabetic animals [19–21]. In our immunohistochemical study we also showed increased immunoreactivity of VEGF in the SDT-NRS and SDT-PR rats, with the difference between these two groups being the intensity of immunoreactivity and location of staining in the vascular endothelial cells. Previous reports on the retina of STZ rats have shown high expression of VEGF mRNA in the ganglion cell layer, the inner nuclear layer and the outer nuclear layer, whereas no VEGF expression was found in normal control rats [19, 21]. The STZ rats were reported to have no ischaemic changes in the retina; however, VEGF expression was higher than in normoglycaemic controls, similar to our finding in SDT rats. Intense staining of VEGF antibody to vascular endothelial cells has also been observed in human proliferative diabetic retinopathy [17, 22]. These studies found intense immunoreactivity for VEGF in the fibrovascular membrane, the vascular endothelial cells, the ganglion cell layer and the inner nuclear layer. The VEGF immunohistochemistry results of our study appear to be similar to those reported in human diabetic retinopathy.
In a mouse model of hypoxia-induced retinal neovascularisation it has been shown that upregulation of VEGF mRNA secondary to large areas of vascular non-perfusion results in massive retinal neovascularisation . In contrast to this model of hypoxia-induced retinopathy, neither SDT nor STZ rats develop areas of vascular non-perfusion. Accordingly, we hypothesise that there are mechanisms other than hypoxia that stimulate the retina to produce VEGF.
Why, then, do SDT rats develop retinal neovascularisation without ischaemic change? One possible reason is the change in the vitreo-retinal interface. In diabetic traction retinal detachment in the human eye, the posterior hyaloid membrane plays a major role in the development of ocular proliferation . It has also been shown in human diabetic retinopathy that the site where vitreous adhesion persists is very likely to be the base for vascular proliferation . In SDT rats, azan staining revealed some adherence, presumably of vitreous cortex, to the retina in SDT-NRS and SDT-PR rats, but not in SDT-control rats. This finding indicates that hyperglycaemia, high levels of VEGF expression, or other factors specific to the SDT diabetic rat caused thickening of the posterior vitreous cortex or modified vitreo-retinal interactions [25, 26].
The other possible reason why diabetic rat models such as the STZ rat reportedly never develop pre-retinal neovascularisation  is that diabetic rodents tend not to live long enough to develop severe stages of diabetic retinopathy. However, while the STZ rat is not able to survive without insulin treatment, the SDT rat is able to live for long periods without medical support. This allows the retinal vasculature to be exposed to high levels of VEGF for a longer period.
As described above, there appear to be differences between the SDT rat model of diabetic retinopathy and human proliferative diabetic retinopathy, as the SDT rat develops retinal neovascularisation without prominent retinal ischaemia. However, the SDT rat is a very unique model for ocular neovascularisation caused by increased expression of VEGF secondary to hyperglycaemia. Therefore, we consider the SDT rat a useful model for the further study of ocular neovascularisation and the interaction between VEGF and vascular endothelial cells.
The SDT rats were kindly provided by the SDT rat study group (Torii Pharmaceutical Company, Tokyo, Japan).